| Literature DB >> 35456087 |
Liziane Cristine Malaquias da Silva1, Fernanda da Silva Platner1, Lauany da Silva Fonseca1, Virgílio Frota Rossato1, Dian Carlos Pereira de Andrade2, João de Sousa Valente3, Susan Diana Brain3, Elizabeth Soares Fernandes1,2.
Abstract
The Chikungunya virus (CHIKV) can cause long lasting symptoms and manifestations. However, there is little information on which ocular ones are most frequent following infection. We performed a systematic review (registered in the International Prospective Register of Systematic Reviews; no CRD42020171928) to establish the most frequent ocular manifestations of CHIKV infection and their associations with gender and age. Articles published until September 2020 were selected from PubMed, Scielo, Cochrane and Scopus databases. Only studies with CHIKV-infected patients and eye alterations were included. Reviews, descriptive studies, or those not investigating the human ocular manifestations of CHIKV, those with patients with other diseases and infections, abstracts and studies without relevant data were excluded. Twenty-five studies were selected for inclusion. Their risk of bias was evaluated by a modified Newcastle-Ottawa scale. The most frequent ocular symptoms of CHIKV infection included ocular pain, inflammation and reduced visual acuity, whilst conjunctivitis and optic neuritis were the most common manifestations of the disease. These occurred mostly in individuals of 42 ± 9.5 years of age and woman. The few available reports on CHIKV-induced eye manifestations highlight the need for further research in the field to gather more substantial evidence linking CHIKV infection, the eye and age/gender. Nonetheless, the data emphasizes that ocular alterations are meaningful occurrences of CHIKV infection which can substantially affect quality of life.Entities:
Keywords: Chikungunya infection; ocular manifestations; ocular symptoms; systematic review
Year: 2022 PMID: 35456087 PMCID: PMC9028588 DOI: 10.3390/pathogens11040412
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Flow diagram of the search process and study selection.
Prevalence of ocular manifestations in patients diagnosed with CHIKV.
| Reference | Origin | Type of Study | Patients | Method of CHIKV Diagnosis | Patients with CHIKV ( | Patients Presenting Ocular Symptoms/Manifestations ( | % of Patients Presenting Ocular Symptoms/Manifestations |
|---|---|---|---|---|---|---|---|
| KANNAN et al. [ | India | Cross sectional | All age groups, men and women | Laboratory test/clinical symptoms | 354 | 41 | 11.6% |
| ROSE et al. [ | India | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 10 | 10 | 100% |
| PERRET et al. [ | Chile | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 16 | 8 | 50% |
| ARROYO-ÁVILA et al. [ | Puerto Rico | Cross sectional | Teens and adults, men and women | Laboratory test/clinical symptoms | 172 | 75 | 43.6% |
| VIJAYAKUMAR et al. [ | India | Cross sectional | All age groups, men and women | Clinical symptoms | 1913 | 419 | 21.9% |
| BABU et al. [ | India | Cross sectional | All age groups, men and women | Laboratory test | 2 | 2 | 100% |
| KAWALI et al. [ | India | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 6 | 2 | 33.3% |
| PANATO et al. [ | Brazil | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 130 | 32 | 24.6% |
| DEEBA et al. [ | Bangladesh | Cross sectional | All age groups, men and women | Clinical symptoms | 1326 | 817 | 61.7% |
| LALITHA et al. [ | India | Cross sectional | Adults, men and women | Laboratory test | 37 | 37 | 100% |
| MAHENDRADAS et al. [ | India | Cross sectional | Adults, men and women | Laboratory test | 9 | 9 | 100% |
| ULLOA-PADILLA et al. [ | Puerto Rico | Cross sectional | Adults, men and women | Laboratory test | 139 | 42 | 30.2% |
| DEL CARPIO-ORANTES et al. [ | Mexico | Cross sectional | Adults, men and women | Clinical symptoms | 1410 | 151 | 10.7% |
| MITTAL et al. [ | India | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 14 | 4 | 28.6% |
| KHAREL (SITAULA) et al. [ | India | Cross sectional | * | Laboratory test | 1 | 1 | 100% |
| REZZA et al. [ | Italy | Cross sectional | All age groups, men and women | Clinical symptoms | 205 | 31 | 15.1% |
| HOCHEDEZ et al. [ | Africa/France | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 22 | 1 | 4.5% |
| PAUL et al. [ | India | Cross sectional | Adults, men and women | Laboratory test/clinical symptoms | 122 | 21 | 17.2% |
| STAIKOWSKY et al. [ | France | Cross sectional | Adults, men and women | Clinical symptoms | 221 | 16 | 7.2% |
| MANIMUNDA et al. [ | India | Cross sectional | All age groups, men and women | Laboratory test | 203 | 49 | 24.1% |
| CHOPRA et al. [ | India | Cross sectional | All age groups, men and women | Laboratory test/clinical symptoms | 509 | 36 | 7.1% |
| VISHWANATH et al. [ | India | Cross sectional | Adults, women | Laboratory test | 1 | 1 | 100% |
| BABU et al. [ | India | Cross sectional | * | Laboratory test | 1 | 1 | 100% |
| MAHENDRADAS et al. [ | Germany | Cross sectional | Teens and adults, men and women | Laboratory test/clinical symptoms | 3 | 3 | 100% |
| KAWALI et al. [ | India | Cross sectional | * | Laboratory test/clinical symptoms | 5 | 5 | 100% |
* Data unavailable in the article.
Prevalence of eye inflammation in patients diagnosed with Chikungunya virus.
| Reference | Origin | Patients with CHIKV (n) | Patients Presenting Eye Inflammation | |||
|---|---|---|---|---|---|---|
| Total of Patients ( | Male ( | Female ( | Age (Mean) | |||
| KANNAN et al. [ | India | 354 | 27 | * | * | * |
| VIJAYAKUMAR et al. [ | India | 1913 | 419 | * | * | * |
| DEEBA et al. [ | Bangladesh | 1326 | 749 | * | * | * |
| LALITHA et al. [ | India | 37 | 37 | 16 | 21 | 44.2 |
| MAHENDRADAS et al. [ | India | 9 | 2 | 2 | 0 | 61.5 |
| ULLOA-PADILLA et al. [ | Puerto Rico | 139 | 55 | * | * | * |
| MITTAL et al. [ | India | 14 | 1 | * | * | * |
| KHAREL (SITAULA) et al. [ | India | 1 | 1 | * | * | * |
| MANIMUNDA et al. [ | India | 203 | 38 | * | * | * |
| VISHWANATH et al. [ | India | 1 | 1 | 1 | 0 | 27 |
| BABU et al. [ | India | 1 | 1 | * | * | * |
| Total of patients: | 3998 | Patients with the symptom: | 1331 | % of patients with the symptom: | 33% | |
* Data unavailable in the original article.
Prevalence of visual defects in patients diagnosed with Chikungunya virus.
| Reference | Origin | Patients with CHIKV ( | Patients Presenting Visual Defects | |||
|---|---|---|---|---|---|---|
| Total of Patients ( | Men ( | Women ( | Age (Mean) | |||
| ROSE et al. [ | India | 10 | 10 | 3 | 7 | 35.8 |
| BABU et al. [ | India | 2 | 2 | 0 | 2 | 45 |
| KAWALI et al. [ | India | 6 | 2 | * | * | * |
| DEEBA et al. [ | Bangladesh | 1326 | 230 | * | * | * |
| LALITHA et al. [ | India | 37 | 37 | * | * | * |
| MAHENDRADAS et al. [ | India | 9 | 7 | 3 | 4 | 50.7 |
| ULLOA-PADILLA et al. [ | Puerto Rico | 139 | 2 | * | * | * |
| MITTAL et al. [ | India | 14 | 14 | 5 | 9 | 45.8 |
| VISHWANATH et al. [ | India | 1 | 1 | 1 | 0 | 27 |
| BABU et al. [ | India | 1 | 1 | * | * | * |
| Total of patients: | 575 | Patients with the symptom: | 137 | % of patients with the symptom: | 23% | |
* Data unavailable in the original article.
Prevalence of eye pain in patients diagnosed with Chikungunya virus.
| Reference | Origin | Patients with CHIKV ( | Patients Presenting Eye Pain | |||
|---|---|---|---|---|---|---|
| Total of Patients ( | Men ( | Women ( | Age (Mean) | |||
| KANNAN et al. [ | India | 354 | 41 | * | * | * |
| ROSE et al. [ | India | 10 | 10 | 3 | 7 | 35.8 |
| PERRET et al. [ | Chile | 16 | 8 | * | * | * |
| ARROYO-ÁVILA et al. [ | Puerto Rico | 172 | 75 | * | * | * |
| MAHENDRADAS et al. [ | India | 9 | 2 | 1 | 1 | 59 |
| MITTAL et al. [ | India | 14 | 1 | 1 | 0 | 25 |
| Total of patients: | 1545 | Patients with the symptom: | 306 | % of patients with the symptom: | 19% | |
* Data unavailable in the original article.
Prevalence of ocular manifestations in patients diagnosed with CHIKV.
| Reference | Patients with CHIKV ( | Corneal Involvement | Conjunctivitis | Episcleritis | Optic Neuritis | Uveitis | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total of Patients ( | Women ( | Men ( | Age (Mean) | Total of Patiens ( | Women ( | Men ( | Age (Mean) | Total of Patiens ( | Women ( | Men ( | Age (Mean) | Total of Patiens ( | Women ( | Men ( | Age (Mean) | Total of Patiens ( | Women ( | Men ( | Age (Mean) | ||
| ROSE et al. [ | 10 | 10 | 3 | 7 | 35.8 | ||||||||||||||||
| BABU et al. [ | 2 | 2 | 0 | 2 | 45 | ||||||||||||||||
| KAWALI et al. [ | 6 | 2 | * | * | * | ||||||||||||||||
| LALITHA et al. [ | 37 | 3 | * | * | * | 8 | * | * | * | 20 | * | * | * | ||||||||
| MAHENDRADAS et al. [ | 9 | 1 | 1 | 0 | 63 | 8 | 3 | 5 | 51.2 | ||||||||||||
| ULLOA-PADILLA et al. [ | 139 | 27 | * | * | * | 13 | |||||||||||||||
| DEL CARPIO-ORANTES et al. [ | 1410 | 151 | * | * | * | ||||||||||||||||
| MITTAL et al. [ | 14 | 12 | 5 | 7 | 46.5 | ||||||||||||||||
| KHAREL (SITAULA) et al. [ | 1 | 1 | * | * | * | ||||||||||||||||
| REZZA et al. [ | 205 | 7 | * | * | * | ||||||||||||||||
| STAIKOWSKY et al. [ | 221 | 16 | * | * | * | ||||||||||||||||
| MANIMUNDA et al. [ | 203 | 49 | * | * | * | ||||||||||||||||
| VISHWANATH et al. [ | 1 | 1 | 1 | 0 | 27 | ||||||||||||||||
| BABU et al. [ | 1 | 1 | * | * | * | ||||||||||||||||
| MAHENDRADAS et al. [ | 3 | 3 | * | * | * | ||||||||||||||||
| KAWALI et al. [ | 5 | 5 | * | * | * | ||||||||||||||||
* Data unavailable in the original article.
Figure 2Quality assessment of the selected research papers using a modified version of the Newcastle-Ottawa scale for analysis of risk of bias (RoB). Green/positive indicates items that were judged as low RoB; Yellow/negative indicates items that were judged with some concerns (moderate RoB). RoB; Red/X indicates items that were judged as high RoB [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37].
Figure A1Search strategies used in each database.
Modified version of the Newcastle-Ottawa scale used in this review.
| Sample Representativeness | Sample Size | Non-Respondents | Ascertainment of Exposure | Comparability | Assessment of Outcome | Statistical Analysis | Follow-Up Time |
|---|---|---|---|---|---|---|---|
| (a) Truly representative of the average population * | (a) Justified and satisfactory * | (a) Comparability between respondents and non-responders’ characteristics is established, and the response rate is satisfactory. * | (a) Validated measurement tool * | (a) The study controls for the most important factor (select one). * | (a) Independent blind assessment * | (a) The statistical test used to analyse the data is clearly described * | (a) The follow up time was long for the outcome to occur * |
* indicates when a criteria of the domain has been fulfilled.